微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 52.02% | -2.52% | -4.95% | 35/159 | 49.67% | 首药控股 | 96.95% | 行业排名> |
| 2026-06-30 | 54.73% | 1.85% | -9.63% | 67/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 60.56% | 18.26% | 11.74% | 55/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 54.2% | -1.53% | 1.57% | 66/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 53.36% | -0.17% | -0.69% | 68/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 53.74% | -5.07% | 4.93% | 69/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 51.21% | -2.47% | -6.96% | 66/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 55.04% | -8.27% | 2.97% | 68/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 53.46% | -5.32% | -5.57% | 70/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 56.61% | 3.15% | 7.81% | 64/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 52.51% | 2.83% | -12.5% | 71/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 60.01% | 18.13% | 6.28% | 53/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 56.46% | 17.2% | 2.88% | 65/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 54.88% | 21.28% | 7.48% | 68/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 51.06% | 16.46% | 0.52% | 73/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 50.8% | 0.67% | 5.44% | 85/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 48.17% | 5.33% | 6.46% | 82/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 45.25% | 8.97% | 3.21% | 88/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 43.84% | 14.15% | -13.1% | 85/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 50.46% | -1.65% | 10.33% | 82/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 45.73% | -7.7% | 10.14% | 79/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 41.53% | -14.31% | 8.11% | 94/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 38.41% | -13.76% | -25.13% | 88/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 51.3% | 6.28% | 3.54% | 77/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 49.55% | 5.14% | 2.25% | 68/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 48.46% | 2.81% | 8.8% | 75/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 44.54% | -5.77% | -7.73% | 73/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 48.27% | 8.09% | 2.43% | 80/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 47.13% | 3.01% | -0.02% | 64/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 47.14% | 8.09% | -0.28% | 67/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 47.27% | 8.94% | 5.84% | 63/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 44.66% | 7.4% | -2.38% | 81/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 45.75% | 10.91% | 4.91% | 61/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 43.61% | 5.53% | 0.5% | 66/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 43.39% | 14.6% | 4.35% | 63/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 41.58% | 0.11% | 0.81% | 75/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 41.25% | 4.22% | -0.18% | 56/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 41.32% | 6.24% | 9.14% | 57/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 37.86% | -4.83% | -8.85% | 55/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 41.54% | -16.71% | 4.96% | 66/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 39.58% | -25.44% | 1.75% | 47/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 38.9% | -27.66% | -2.23% | 52/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 39.78% | -10.33% | -20.23% | 41/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |